Two-Drug combo shows promise for Tough-to-Treat lymphomas

This early-phase study tested a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system attack cancer) and vorinostat (a drug that blocks enzymes cancer cells need to grow)—in 52 adults with certain types of lymphoma that had returned or stopped responding to prior treatments. The main goals were to find the safest dose of vorinostat when given with pembrolizumab and to check for side effects. While the treatment aims to control the disease, it is not expected to be a cure, and ongoing management may still be needed.